Allurion Technologies Hits 52-Week Low at $1.89 Amidst Major Decline

Allurion Technologies, Inc., a microcap player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of USD 1.89 on October 22, 2025. This significant decline reflects a staggering 93.51% drop in the company's stock price over the past year, contrasting sharply with the S&P 500's performance, which has seen a gain of 15.06% during the same period.
The company's market capitalization stands at approximately USD 17 million, indicating its small size within the industry. Allurion Technologies has faced challenges, including a negative book value and a weak ability to service its debt, as evidenced by a poor EBIT to interest ratio of -13.96. Additionally, the company reported net sales of only USD 3.38 million, marking a low point in its financial performance.

With a return on equity of 68.55%, the company has shown some operational efficiency, but the overall financial health remains concerning due to ongoing losses and a negative net worth. The stock's performance has consistently lagged behind the S&P 500 over the last three years, highlighting the difficulties faced by Allurion Technologies in the current market landscape.